Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2011. Refer to TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | thalidomide (Thalidomide Celgene®) | |
| Formulation | 50 mg capsule | |
| Reference number | 309 | |
| Indication | In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged 65 or older or ineligible for high-dose chemotherapy |
|
| Company | Celgene Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Full | |
| Status | Superseded | |
| Advice number | 0109 | |
| NMG meeting date | 27/01/2009 | |
| AWMSG meeting date | 25/02/2009 | |
| Ratification by Welsh Government | 16/03/2009 | |
| Date of issue | 17/03/2009 | |
| NICE guidance | TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
|